[Optimizing iron therapy in hemodialysis: a prospective long term clinical study]

Area of Science:

• Nephrology
• Hematology
• Pharmacology

Context:

• Intravenous iron therapy is standard for hemodialysis patients.
• Optimizing long-term iron management requires identifying the best monitoring marker.
• Current markers like ferritin and hypochromic erythrocytes show limitations.

Purpose:

• To prospectively evaluate iron markers for optimizing intravenous iron therapy in hemodialysis.
• To compare transferrin saturation (TSAT), ferritin (FERR), hypochromic erythrocytes (HYPO), and reticulocyte hemoglobin content (HCr).
• To determine the optimal iron dose and monitoring marker for long-term treatment.

Summary:

• A 6-month cohort study infused low molecular weight iron dextran at 100, 150, and 200 mg/month.
• TSAT and HCr specifically responded to iron doses, but TSAT changes were more significant (65%) than HCr (6%).
• Albumin levels increased significantly; hemoglobin, EPO doses, and C-reactive protein remained stable. HYPO and FERR changes were non-specific.

Impact:

• Results suggest 200 mg/month of intravenous iron is effective.
• Transferrin saturation (TSAT) is identified as the most suitable marker for nephrologists to optimize iron therapy.
• This finding aids in personalized and effective long-term iron management for hemodialysis patients.